Search for: "Cephalon Inc." Results 21 - 40 of 171
Sort by Relevance | Sort by Date
RSS Subscribe: 20 results | 100 results
4 Jun 2015, 8:00 am by Greene LLP
A federal judge in Pennsylvania has allowed the majority of a relator’s False Claims Act case against Cephalon Inc. to proceed, alleging a kickback scheme involving off-label drug marketing. [read post]
28 May 2015, 9:30 pm by RegBlog
Cephalon, Inc. settled with the Federal Trade Commission (FTC) for allegedly reducing competition by preventing the sale of generic versions of the sleep-disorder drug, Provigil. [read post]
1 Apr 2015, 11:51 am by Montgomery McCracken
On March 23, 2015, the United States District Court for the Eastern District of Pennsylvania denied certification of a nationwide class of third party payors (“TPPs”) asserting unjust enrichment claims against Cephalon, Inc. [read post]
12 Nov 2014, 10:15 am
 Teva's subsidiary Celaphon had provided documents at the request of the city of Chicago on the basis that their trade secrets would be protected but that "since that time, in a series of written and verbal communications, the city took the position that it would disclose Cephalon's confidential documents to the press. [read post]
25 Jul 2014, 1:13 pm
Cephalon, Inc., is a third party payor case where plaintiffs – workers compensation insurers – claimed that they were injured by paying for prescriptions for defendant drug company’s  pain medications which were written as a result of its alleged off-label marketing of the drug. [read post]
9 Jun 2014, 11:25 am
Last month, as reported by the Los Angeles Times, the California counties of Orange and Santa Clara sued Actavis, Endo Health Solutions Inc., Johnson & Johnson's Janssen Pharmaceuticals, Purdue Pharma and Teva Pharmaceutical Industries' Cephalon Inc. for causing the national prescription drug epidemic. [read post]
6 Feb 2014, 6:31 am by RatnerPrestia
FAS Technologies, Inc., is it appropriate for this court to accord any deference to any aspect of trial court claim construction rulings? [read post]
13 Jan 2014, 4:02 am
Take for example, the pharmaceuticals case of Cephalon Inc v Orchid Europe Ltd [2010] EWHC 2945 (Pat) [briefly noted on PatLit here] in which Floyd J (as he was) treated the issue of who is likely to suffer the most irreparable harm as the key factor in the balance of convenience assessment itself: "Balance of convenienceThere is no dispute as to the approach which I should apply. [read post]
3 Oct 2013, 7:07 am by Docket Navigator
Cephalon, Inc. et. al., 2-06-cv-02768 (PAED October 1, 2013, Order) (Goldberg, J.) [read post]
10 Jul 2013, 12:00 am
 While synthesizing and screening compounds is considered routine experimentation, the Court noted in Cephalon, Inc. v. [read post]